Company: VisionCare Ophthalmic
Based: Saratoga, CA
Investors: Saints Capital, Giza Ventures, General iFinancial Holdings, BSI SA, Pitango Venture Capital, Three Arch Partners, ONSET Ventures, and Newbury Acquisitions Fund/Infinity CSVC Management
Scoop: VisionCare Ophthalmic started off the year strong with a $31 million Series E venture capital round, filled with new and existing investors. The company, which focuses on visual prosthetics, will use the funding for its telescopic prosthesis, designed for end-stage age-related macular degeneration. The implant, which is smaller than a pea, will be planted in one ye of the AMD patient. VisionCare plans to allocate the funding to further develop its sales and marketing for the product.
"The combination of an aging population and lack of effective end-stage AMD treatment options make VisionCare's telescope implant a vital addition to this high-value and high-growth segment of the ophthalmic space," said Dr. Zack Scott, VP at Saints Capital, in a release. "We have been impressed by VisionCare's abilities during the clinical development phase, and look forward to their progress as they bring this potentially life-changing treatment to market."